Global Blood Therapeutics (GBT)

Global Blood Therapeutics Stock Forecast & Price Target

See the Price Targets and Ratings of:

Analyst Rating Consensus

2 Buy
12 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Blood Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GBT Stock Price Prediction

Average Price Target

▲(0.13% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months. The average price target is $68.58 with a high forecast of $72.00 and a low forecast of $66.00. The average price target represents a 0.13% change from the last price of $68.49.
Highest Price Target$72.00Average Price Target$68.58Lowest Price Target$66.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Upside / Downside
Upgrade Banner
William Blair
Global Blood Therapeutics downgraded to Market Perform from Outperform at William BlairGlobal Blood Therapeutics downgraded to Market Perform from Outperform at William Blair
Analysts Are Neutral on Top Healthcare Stocks: Global Blood Therapeutics (GBT), Cerevel Therapeutics Holdings (CERE)
Cantor Fitzgerald
Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5
Goldman Sachs
Global Blood Therapeutics (GBT) Acquisition Would Make Sense - Goldman SachsGoldman Sachs analyst Paul Choi reiterated a Buy rating and $66.00 price target on Global Blood Therapeutics (NASDAQ: GBT) following reports the company is drawing takeover interest from large pharmaceutical companies. The analyst said a deal for would be consistent with the recent pick up in later-stage biotech deal announcements.
J.P. Morgan
JP Morgan Maintains Neutral on Global Blood Therapeutics, Lowers Price Target to $36
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

GBT Stock Forecast FAQ

What is GBT’s average 12-month price target, according to analysts?
Based on analyst ratings, Global Blood Therapeutics’s 12-month average price target is $68.58.
    What is GBT’s upside potential, based on the analysts’ average price target?
    Global Blood Therapeutics has 0.13% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GBT a Buy, Sell or Hold?
          Global Blood Therapeutics has a conensus rating of Hold which is based on 2 buy ratings, 12 hold ratings and 0 sell ratings.
            What is Global Blood Therapeutics’s price target?
            The average price target for Global Blood Therapeutics is $68.58. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $72.00 ,the lowest forecast is $66.00. The average price target represents 0.13% Increase from the current price of $68.49.
              What do analysts say about Global Blood Therapeutics?
              Global Blood Therapeutics’s analyst rating consensus is a ‘Hold. This is based on the ratings of 14 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis